Tennessee Oncology, PLLC

Chattanooga, Tennessee 37404

4 studies enrolling now · 28 studies all time

What they study most

Acinar Cell Carcinoma, Adenocarcinoma of the Gastroesophageal Junction, Advanced Cancer, Advanced Solid Tumor, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Cancer of the Prostate, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Castration-Resistant Prostate Cancer, Chronic Lymphocytic Leukemia

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC — Recruiting now
• Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). — Completed
• Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma — Completed
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations — Completed
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer — Completed
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer — Running, not enrolling
• Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study — Enrolling by invitation
• Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients — Completed
• Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer — Completed
• A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer — Completed
• Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors — Stopped early
• A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors — Completed
• A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma — Completed
• A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer — Completed
• Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) — Completed
• Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) — Stopped early
• Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer — Completed
• A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy — Stopped early
• A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants — Completed
• Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia — Stopped early
• TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy — Stopped early
• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy — Completed
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas — Stopped early